ARWR
Arrowhead Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$86.34
−0.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 669.5M | 829.4M | 3.6M | 240.7M | 243.2M |
| Cost of Revenue | — | — | 18.6M | 12.5M | 10.4M |
| Gross Profit | 669.5M | 829.4M | (15.0M) | 228.2M | 232.8M |
| Operating Expenses | |||||
| R&D Expense | 723.4M | 607.2M | 489.2M | 342.3M | 288.5M |
| SG&A Expense | 171.1M | 121.9M | 96.8M | 90.9M | 124.4M |
| General & Admin Expense | 123.9M | 121.9M | 96.8M | 90.9M | 124.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.5M | 2.0M | — | — | — |
| Total Operating Expenses | 895.9M | 731.1M | 586.0M | 433.2M | 411.3M |
| Cost and Expenses | 895.9M | 731.1M | 604.6M | 445.7M | 421.7M |
| Operating Income (EBIT) | (226.4M) | 98.3M | (601.1M) | (205.0M) | (178.5M) |
| Non-Operating | |||||
| Interest Income | 52.5M | 37.3M | 22.7M | 15.3M | 5.0M |
| Interest Expense | 92.6M | 89.4M | 32.4M | 18.3M | — |
| Net Interest Income | (40.1M) | (52.1M) | (9.6M) | (3.0M) | 5.0M |
| Other Non-Op Income/Expense | (25.6M) | (46.8M) | (11.4M) | (1.5M) | 5.8M |
| Non-Operating Income (excl Interest) | (67.0M) | (42.5M) | (21.0M) | (16.8M) | (5.8M) |
| EBT (Pre-Tax Income) | (252.1M) | 51.5M | (612.5M) | (206.5M) | (172.7M) |
| Income Tax Expense | 20.0M | 21.4M | (2.8M) | 2.8M | 3.8M |
| Bottom Line | |||||
| Net Income | (320.0M) | (1.6M) | (599.5M) | (205.3M) | (176.1M) |
| Earnings from Cont. Ops | (272.1M) | 30.1M | (609.7M) | (209.3M) | (176.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (320.0M) | (1.6M) | (599.5M) | (205.3M) | (176.1M) |
| Per Share | |||||
| Basic EPS | ($2.24) | ($0.01) | ($5.00) | ($1.92) | ($1.67) |
| Diluted EPS | ($2.24) | ($0.01) | ($5.00) | ($1.92) | ($1.67) |
| Revenue Per Share | $4.67 | $6.20 | $0.03 | $2.26 | $2.31 |
| Shares | |||||
| Basic Shares Outstanding | 143.4M | 133.8M | 119.8M | 106.8M | 105.4M |
| Diluted Shares Outstanding | 143.4M | 133.8M | 119.8M | 106.8M | 105.4M |
| Profitability Metrics | |||||
| EBITDA | (140.3M) | 164.8M | (561.5M) | (175.7M) | (162.3M) |
| D&A | 19.1M | 23.9M | 18.6M | 12.5M | 10.4M |
| EBIT | (159.5M) | 140.9M | (580.1M) | (188.2M) | (172.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026